Pramipexole 4.5Mg Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg
Reference Brands: Mirapex (USA)
Category:
Antipsychotropic Drugs
Pramipexole Tablet is a medicine that is used for the treatment of Parkinson Disease and other conditions.
Pramipexole Tablet contains Pramipexole Dihydrochloride Monohydrate as an active ingredient.
Pramipexole Tablet works by increasing the action of chemical receptors in the brain.
Pramipexole 4.5mg Tablets is available in Tablets
and strengths such as 0.125 mg, 0.25 mg, 0.5 mg, 1 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pramipexole 4.5mg Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pramipexole 4.5mg Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pramipexole is a dopamine agonist belonging to the non-ergoline class, widely used in the management of Parkinson’s disease and restless legs syndrome (RLS). It works by directly stimulating dopamine receptors in the brain, helping to compensate for reduced dopamine activity that leads to movement and neurological symptoms. In patients with Parkinson’s disease, pramipexole may be prescribed as monotherapy in early stages or used in combination with levodopa in advanced stages to improve motor control, reduce rigidity, and manage tremors.
Pramipexole is administered orally and is available in both immediate-release and extended-release tablet formulations, allowing flexible dosing based on patient needs. For restless legs syndrome, it helps reduce uncomfortable sensations and the urge to move the legs, particularly during evening or nighttime hours, improving sleep quality.
The medication is marketed globally under brand names such as Mirapex and Sifrol, along with several generic versions. Pramipexole is chemically synthesized and not derived from animal or biological sources. While it is an effective and well-established therapy, safety data regarding use during pregnancy and breastfeeding remain limited, and treatment decisions in such cases should be made under medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing